News
- Author:
- Roxanne Nelson
Publish date: November 30, 2018
Stereotactic radiotherapy is highly effective for controlling brain metastases in patients with renal cell carcinoma, even in those with more than ...
News
- Author:
- Roxanne Nelson
Publish date: October 25, 2018
The risk of line-associated complications was significantly higher with dose-adjusted EPOCH-R therapy, compared with R-CHOP, in patients with aggre...
News
- Author:
- Roxanne Nelson
Publish date: October 23, 2018
Tyrosine kinase inhibitors and immune checkpoint inhibitors show encouraging results in the treatment of alveolar soft part sarcoma
News
- Author:
- Roxanne Nelson
Publish date: October 22, 2018
Regular aspirin use decreased the risk of both ovarian cancer and hepatocellular carcinoma.
News
- Author:
- Roxanne Nelson
Publish date: October 15, 2018
Regular aspirin use decreased the risk of both ovarian cancer and hepatocellular carcinoma.
News
- Author:
- Roxanne Nelson
Publish date: October 5, 2018
Investigational drug epacadostat plus pembrolizumab demonstrated promising antitumor activity and safety in patients with advanced solid tumors.
News
- Author:
- Roxanne Nelson
Publish date: August 14, 2018
Plasma glycosaminoglycan (GAG) measurements can provide accurate diagnostic and prognostic information that may have clinical utility in renal cell...
News
- Author:
- Roxanne Nelson
Publish date: August 10, 2018
Lumpectomy plus radiotherapy is associated with a significant reduction in breast cancer mortality versus lumpectomy or mastectomy alone.
News
- Author:
- Roxanne Nelson
Publish date: May 23, 2018
Tailored frequency-escalated prophylaxis resulted in less use of recombinant factor VIII.
News
- Author:
- Roxanne Nelson
Publish date: April 6, 2018
Use of oral bisphosphonates was associated with a lower risk of developing lung cancer in postmenopausal women, but only those who were never smoke...
News
- Author:
- Roxanne Nelson
Publish date: March 12, 2018
Median PFS was 3.8 months with fruquintinib versus 1.1 months with placebo in heavily pretreated patients with advanced NSCLC.
News
- Author:
- Roxanne Nelson
Publish date: March 7, 2018
There was no evidence of tumor recurrence or metastasis from cRCC for both active surveillance and following surgery when evaluated with a standard...
News
- Author:
- Roxanne Nelson
Publish date: February 2, 2018
In vitro studies show strong results for spray-dried plasma, which could have implications on the battlefield.
News
- Author:
- Roxanne Nelson
Publish date: January 24, 2018
The phase 2 trial included patients who did not respond to erythropoiesis-stimulating agents.
News
- Author:
- Roxanne Nelson
Publish date: January 12, 2018
The risk was predominantly observed in BRCA1 mutation carriers, and disease development generally occurred within 5 years following RRSO.
